NEW YORK, Feb 22 - Luminex has collaborated with Dynacare, a company that runs clinical laboratories, to develop genetic tests using its LabMap technology, the companies announced Thursday.
LabMap uses microspheres to assay nucleic acids, antigen-antibody binding, enzymes, and other receptor-ligand interactions. Small lasers, digital processors, and software allow the system to perform up to 100 assays per drop of fluid.
Under the agreement, Luminex has granted Dynacare the non-exclusive rights to develop clinical assays based on LabMap, and to purchase LabMap consumables and instruments from Luminex for its testing services.
Dynagene, Dynacare's testing arm, will develop high-throughput diagnostic tests for cystic fibrosis and other genetic conditions such as Tay Sachs, Canavan, and Gaucher diseases. Dynagene hopes it can reduce its screening time to between one and two days, from one to two weeks for other laboratories. The parties did not disclose the financial terms of the agreement.
"We are delighted that Dynacare, a national leader in the clinical laboratory industry, has become our partner in adopting the LabMap system," said Luminex CEO Mark Chandler. "Many clinical laboratories are exploring new ways to internalize tests on the LabMap system and this agreement with Dynacare is a powerful example of how our system can be an integral solution in the clinical laboratory."
Luminex has stated that partnerships are key to the company's core marketing strategy for LabMap.